Sharon Bio Medicine Limited reported standalone unaudited earnings results for the quarter ended June 30, 2019. For the quarter, the company reported revenue from operations of INR 441.063 million compared with INR 333.964 million for the same period last year. Loss for the period was INR 561.899 million or INR 2.32 basic and diluted per share as compared with profit Of INR 44.050 million or INR 0.37 basic and diluted per share for the same period last year. Total income was INR 441.505 million against INR 341.700 million a year ago.